Sandostatin for Patients With Androgen Independent Prostate Cancer
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This is an open label, single center Phase II trial of Sandostatin LAR in patients with
hormone refractory prostate cancer. Patients will receive Sandostatin LAR 30 mg
intramuscularly every 28 days. Patients will be treated until the time of disease
progression, unacceptable toxicity or withdrawal of consent. The study will require 27
evaluable patients.